Stockscreener 앱 받기
0.00
100.00%
-5.34
전일 마감가:
$5.34
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$35.98M
수익:
$15.27M
순이익/손실:
$-62.63M
주가수익비율:
0.00
EPS:
-7.3629
순현금흐름:
$-114.74M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$6.95
제너레이션 바이오 Stock (GBIO) Company Profile
명칭
Generation Bio Co
전화
857-529-5908
주소
301 BINNEY STREET, CAMBRIDGE
Compare GBIO vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.00 | 35.98M | 15.27M | -62.63M | -114.74M | -7.3629 |
VRTX
Vertex Pharmaceuticals Inc
|
496.73 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
623.54 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.77 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.28 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.13 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
제너레이션 바이오 Stock (GBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-16 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-08-13 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-10-19 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2021-12-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-07-07 | 개시 | Jefferies | Buy |
| 2020-07-07 | 개시 | Wedbush | Outperform |
모두보기
제너레이션 바이오 주식(GBIO)의 최신 뉴스
Next-Generation Bioconjugation: Meet the Experts - BioPharm International
Certis Belchim and Greenhas Group Partner to Advance Next-Generation Biostimulant Innovation - Global Agriculture
Bionyra brings in $165M for next-generation immune drugs - BioPharma Dive
TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million - PR Newswire
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases - Business Wire
Generation Bio Co (GBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Generation Bio Co (GBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Generation Bio Co (GBIO) Institutional Confidence - TradingKey
Generation Bio Co (GBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Generation Bio Co (GBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Generation Bio Co (GBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Generation Bio Co (GBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Generation Bio Co (GBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
One photon, two reactionsnew catalyst converts CO₂ and biowaste simultaneously - EurekAlert!
One Photon, Two ReactionsNew Catalyst Converts CO2 and Biowaste Simultaneously - AZoM
NOROO Holdings Advances Commercialization of Bio-Based 3-HP Through Major Korean Government Initiative - 巴士的報
Bayer-Aphea.Bio deal targets next-gen bioinsecticides as ag majors continue biologicals push - agnavigator.com
K-Bio Highlights Next-Generation Obesity and Metabolic Disease Drug Achievements at ADA in the US - 아시아경제
Yeoncheon Green Bio Companies Demonstrate Technological Capabilities and Growth Potential at Seoul K-Bio Week - 아시아경제
CG Bio and CG Medtech Present Next-Generation Spinal Treatment Strategy at GSC 2026 - 아시아경제
Samsung widens bet on next-generation biotech - 매일경제
Samsung will create the "Samsung Life Science Fund No. 3" worth 200 billion won to expand investment.. - 매일경제
Howl Bio is speeding up its efforts to target the biopharmaceutical market at home and abroad with a.. - 매일경제
Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026 - The National Law Review
Samsung Epis Holdings opens China R&D hub to boost ADC drug developmentCHOSUNBIZ - Chosunbiz
Generation Bio Co stock (US37148B1061): Eli Lilly deal fuels fresh attention on DNA-delivery special - AD HOC NEWS
Generation Bio stock (US37148B1061): Trial momentum keeps investors watching - AD HOC NEWS
Generation Bio stock: Trial momentum keeps investors watching - AD HOC NEWS
Organic wastes to next-generation bioplastics through intelligent biomanufacturing of polyhydroxyalkanoates - Nature
Cosmax China unveils next-generation bio beauty solutions at China Expo - theinvestor.co.kr
Atlas Venture amends 13G/A on GBIO holdings (GBIO) - Stock Titan
TradingKey - TradingKey
SNU professor Sangwoo Seo’s research team develops next-generation CRISPR biocontainment technology for controlling microbial survival without DNA cleavage - EurekAlert!
ParcelBio Launches with $13 Million in Financing to Advance Next-Generation mRNA Medicines - Business Wire
Samsung Bioepis announced on the 29th that it will sign a memorandum of understanding (MOU) with the.. - 매일경제
XOMA (XOMA) closes Generation Bio acquisition, details cash-plus-CVR terms and LNP assets - Stock Titan
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Firm secures £100k to develop next generation plastics - The Argus
Low-energy path to bioplastics emerges from discarded wood - The Korea Times
Eli Lilly acquires Houston biotech startup for $300M - Houston Chronicle
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates - Business Wire
National Growth Fund Invests in SK Bioscience… Supporting Next-Generation Bio and Vaccine Development - Seoul Economic Daily
From Colossal to Chickens: The Scientists Behind Neion Bio’s Biologics Platform - Genetic Engineering and Biotechnology News
Retail Trends: Why is Generation Bio Co stock going downQuarterly Profit Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
GBIO SEC FilingsGeneration Bio Co. 10-K, 10-Q, 8-K Forms - Stock Titan
Fed Meeting: Will Generation Bio Co benefit from AI trends2026 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
Sell Signal: Will Generation Bio Co benefit from AI trends2026 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Stipple Bio raises $100M Series A to advance next-gen cancer therapies - Indian Pharma Post
Generation Bio Co stock: Why this gene therapy innovator merits your watchlist now - AD HOC NEWS
XOMA SEC FilingsXOMA Royalty Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
Daito Trust Construction to merge two companies involved in biomass power generation into DAITO BIO ENERGY - kentaku.co.jp
제너레이션 바이오 (GBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
1.75%
자본화:
|
볼륨(24시간):